Rapid velaglucerase alfa infusion for Gaucher disease: 5-year data
Intern Med J
.
2022 Sep;52(9):1645-1646.
doi: 10.1111/imj.15898.
Authors
Michal Becker-Cohen
1
,
Jeff Szer
2
,
Naama Arbel
3
,
Dafna Frydman
1
,
Tama Dinur
1
,
Majdolene Istaiti
1
,
Shoshana Revel-Vilk
1
,
Ari Zimran
1
Affiliations
1
Gaucher Unit, Shaare Zedek Medical Center, Affiliated with Hadassah-Hebrew University Medical School, Jerusalem, Israel.
2
Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Department of Medicine University of Melbourne, Melbourne, Victoria, Australia.
3
Medison Pharma, Petah Tikva, Israel.
PMID:
36100564
DOI:
10.1111/imj.15898
No abstract available
Publication types
Letter
MeSH terms
Enzyme Replacement Therapy
Gaucher Disease* / drug therapy
Glucosylceramidase / therapeutic use
Humans
Substances
Glucosylceramidase